Literature DB >> 11169731

Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells.

X Wang1, G P Studzinski.   

Abstract

Activation of ERK1 and ERK2 protein kinases has been implicated in diverse cellular processes, including the control of cell proliferation and cell differentiation (Marshall [1995] Cell 80:179). In human myeloblastoid leukemia HL60 cells rapid (ca. 15 min) but transient activation of ERK1/2 has been reported following induction of macrophage/monocyte differentiation by phorbol esters, or by very high (10(-6) M) concentrations of 1,25-dihydroxyvitamin D(3) (1,25D3), while retinoic acid-induced granulocytic differentiation was accompanied by sustained activation of ERK1/2. We report here that monocytic differentiation of HL60 cells induced by moderate (10(-9) to 10(-7) M) concentrations of 1,25D3 could be divided into at least two stages. In the first phase, which lasts 24-48 h, the cells continued in the normal cell cycle while expressing markers of monocytic phenotype, such as CD14. In the next phase the onset of G1 cell cycle block became apparent and expression of CD11b was prominent, indicating a more mature myeloid phenotype. The first phase was characterized by high levels of ERKs activated by phosphorylation, and these decreased as the cells entered the second phase, while the levels of p27/Kip1 increased at that time. Serum-starved or PD98059-treated HL60 cells had reduced growth rate and slower differentiation, but the G1 block also coincided with decreased levels of activated ERK1/2. The data suggest that the MEK/ERK pathway maintains cell proliferation during 1,25D3-induced monocytic differentiation of HL60 cells, but that ERK1/2 activity becomes suppressed during the later stages of differentiation, and the consequent G1 block leads to "terminal" differentiation. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169731     DOI: 10.1002/1097-4644(20010315)80:4<471::aid-jcb1001>3.0.co;2-j

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  44 in total

1.  Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.

Authors:  Xuening Wang; Jonathan S Harrison; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-28       Impact factor: 4.292

2.  Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3.

Authors:  Ewa Marcinkowska; Edward Garay; Elzbieta Gocek; Agnieszka Chrobak; Xuening Wang; George P Studzinski
Journal:  Exp Cell Res       Date:  2006-04-19       Impact factor: 3.905

Review 3.  Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Authors:  Daniel E Johnson
Journal:  Adv Enzyme Regul       Date:  2007-11-19

Review 4.  Differentiation therapy of leukemia: 3 decades of development.

Authors:  Daniel Nowak; Daphne Stewart; H Phillip Koeffler
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

5.  MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis.

Authors:  Elzbieta Gocek; Xuening Wang; Xiuping Liu; Chang-Gong Liu; George P Studzinski
Journal:  Cancer Res       Date:  2011-08-04       Impact factor: 12.701

Review 6.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

7.  Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region.

Authors:  X Wang; T-T Wang; J H White; G P Studzinski
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

Review 8.  Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks.

Authors:  René Huber; Daniel Pietsch; Johannes Günther; Bastian Welz; Nico Vogt; Korbinian Brand
Journal:  Cell Mol Life Sci       Date:  2013-03-24       Impact factor: 9.261

9.  Mechanisms of nuclear vitamin D receptor resistance in Harvey-ras-transfected cells.

Authors:  Laura M Taber; Lynn S Adams; Dorothy Teegarden
Journal:  J Nutr Biochem       Date:  2008-10-01       Impact factor: 6.048

10.  A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines.

Authors:  Piotr Jasinski; Brandon Welsh; Jorge Galvez; David Land; Pawel Zwolak; Lori Ghandi; Kaoru Terai; Arkadiusz Z Dudek
Journal:  Invest New Drugs       Date:  2007-10-24       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.